Zeke Capital Advisors LLC Sells 38,271 Shares of Johnson & Johnson (JNJ)

Zeke Capital Advisors LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 46.1% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 44,681 shares of the company’s stock after selling 38,271 shares during the quarter. Zeke Capital Advisors LLC’s holdings in Johnson & Johnson were worth $5,422,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in JNJ. Financial Gravity Wealth Inc. purchased a new position in Johnson & Johnson in the 1st quarter worth approximately $105,000. FNY Investment Advisers LLC purchased a new position in Johnson & Johnson in the 2nd quarter worth approximately $117,000. Princeton Capital Management LLC purchased a new position in Johnson & Johnson in the 1st quarter worth approximately $141,000. Smart Portfolios LLC purchased a new position in Johnson & Johnson in the 1st quarter worth approximately $150,000. Finally, Live Your Vision LLC lifted its holdings in Johnson & Johnson by 58.3% in the 2nd quarter. Live Your Vision LLC now owns 1,363 shares of the company’s stock worth $172,000 after purchasing an additional 502 shares in the last quarter. Institutional investors own 66.67% of the company’s stock.

In related news, COO Michael E. Sneed sold 29,000 shares of the stock in a transaction on Monday, August 27th. The stock was sold at an average price of $134.80, for a total transaction of $3,909,200.00. Following the sale, the chief operating officer now owns 59,124 shares in the company, valued at approximately $7,969,915.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CAO Ronald A. Kapusta sold 7,899 shares of the stock in a transaction on Friday, September 7th. The shares were sold at an average price of $137.18, for a total value of $1,083,584.82. Following the sale, the chief accounting officer now owns 25,725 shares in the company, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. 0.22% of the stock is owned by corporate insiders.

JNJ has been the topic of a number of research analyst reports. Raymond James boosted their price target on Johnson & Johnson from $144.00 to $149.00 and gave the stock an “outperform” rating in a report on Wednesday. Credit Suisse Group boosted their price target on Johnson & Johnson from $149.00 to $152.00 and gave the stock an “outperform” rating in a report on Wednesday. Goldman Sachs Group raised Johnson & Johnson from a “sell” rating to a “neutral” rating in a report on Thursday, July 12th. Sanford C. Bernstein initiated coverage on Johnson & Johnson in a report on Wednesday, June 27th. They issued a “market perform” rating and a $129.00 price target on the stock. Finally, ValuEngine raised Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and eleven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus target price of $144.25.

Shares of JNJ opened at $139.46 on Thursday. The company has a market cap of $370.70 billion, a PE ratio of 19.10, a PEG ratio of 2.19 and a beta of 0.70. Johnson & Johnson has a 1 year low of $118.62 and a 1 year high of $148.32. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.33 and a current ratio of 1.65.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.03 by $0.02. The business had revenue of $20.35 billion for the quarter, compared to analysts’ expectations of $20.05 billion. Johnson & Johnson had a return on equity of 32.79% and a net margin of 1.70%. The company’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same period in the prior year, the firm earned $1.90 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 8.14 EPS for the current fiscal year.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Do stock splits help investors?

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply